$1.54 Billion is the total value of Avoro Capital Advisors LLC's 52 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DERM | DERMIRA INC | $42,271,000 | +3.0% | 1,520,000 | 0.0% | 2.74% | -13.9% | |
| MYOK | MYOKARDIA INC | $16,765,000 | -1.7% | 398,207 | 0.0% | 1.09% | -17.8% | |
| INTEC PHARMA LTD | $11,308,000 | -42.5% | 2,195,705 | 0.0% | 0.73% | -51.9% | ||
| ALIM | ALIMERA SCIENCES INC | $8,301,000 | -1.5% | 6,241,581 | 0.0% | 0.54% | -17.7% | |
| IMMU | IMMUNOMEDICS INCcall | $8,225,000 | +30.6% | 875,000 | 0.0% | 0.53% | +9.0% | |
| VIVE | VIVEVE MEDICAL INC | $5,135,000 | -5.2% | 1,033,276 | 0.0% | 0.33% | -20.7% | |
| PERNIX THERAPEUTICS HOLDINGS INCconvertible debt | $2,530,000 | +0.2% | 6,000,000 | 0.0% | 0.16% | -16.3% | ||
| CLLS | CELLECTIS S Asponsored ads | $2,282,000 | +2.5% | 78,289 | 0.0% | 0.15% | -14.5% | |
| ONS | ONCOBIOLOGICS INC | $889,000 | -5.0% | 683,531 | 0.0% | 0.06% | -20.5% | |
| ONSIW | ONCOBIOLOGICS INC - WARRANT Awarrant | $7,000 | -75.0% | 233,333 | 0.0% | 0.00% | -100.0% | |
| ONSIZ | ONCOBIOLOGICS INC - WARRANT Bwarrant | $5,000 | -58.3% | 233,333 | 0.0% | 0.00% | -100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.